ReviewBiomedicines2026
Understanding the Role of Hypothalamic-Pituitary-Gonadal Axis in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, mostly occurring during the reproductive period, and it is diagnosed more frequently in women. The sex biases in the incidence and course of both MS and its most commonly used animal model, experimental autoimmune encephalomyelitis (EAE), seem to be driven by fluctuations in sex hormones. The regulation of sex hormone synthesis and release relies on a dynamic hierarchical system-the hypothalamic-pituitary-gonadal (HPG) axis. This review provides an overview of the main characteristics of MS and EAE pathologies and explains the structure and function of the HPG axis in order to better understand the sex-specific features of MS and EAE. The particular role of sex hormones as culprits in the sex differences in these pathologies is covered, as well as the disturbances to the HPG axis that arise as a consequence of MS/EAE course. Finally, the use of sex hormones as potential adjuvant therapeutics for MS is discussed. Given the complexity and dynamism in the regulation of the HPG axis, an individual, holistic approach should be taken when considering sex hormones for the treatment of MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.